RBC Capital Starts Biohaven Pharmaceutical Holding (BHVN) at Outperform, Sees Nearer-term Catalysts

RBC Capital analyst Leonid Timashev initiates coverage on Biohaven Pharmaceutical Holding (NYSE: BHVN) with a Outperform rating and a price target of $62.00.

The analyst commented, "Initiating coverage on BHVN with an Outperform, Speculative Risk rating and a $62 price target. We like the way BHVN identifies promising technologies and targets and then leverages its mgmt expertise to optimize the development path based on competitor data to become a fast-follower in high-value therapeutic areas. In particular, we see this playbook leading to success in epilepsy, where we believe the market can support two winning Kv7 modulators, and see BHV-7000 as having $1B+ potential. While we see some of the nearer-term catalysts as high reward/risk, we believe there is significant value to be unlocked over the long-term as data from the Kv7, degrader, and other pipeline programs matures."

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $49.11 yesterday.

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• Williams-Sonoma (WSM) PT Raised to $260 at RBC Capital
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy